Side-by-side · Research reference

AHK-CuvsMatrixyl

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-MechanisticHUMAN-REVIEWED14/43 cited

BAnimal-MechanisticHUMAN-REVIEWED9/39 cited

AHK-Cu

Tripeptide-Copper Complex · Cosmetic

10⁻¹² – 10⁻⁹ MActive range (in vitro)Pyo 2007

Dermal papilla cellsPrimary targetPyo 2007

TopicalRoute

Topical · Scalp / Skin

Matrixyl

Cosmeceutical Pentapeptide · Topical Anti-Aging

TopicalRoute

5-AALength (KTTKS)Gomes 2022

Collagen I/IIIPrimary targetPaccola 2025

Topical · Dermal · Twice Daily

01Mechanism of Action

Parameter

AHK-Cu

Matrixyl

Primary target

Dermal papilla cells (DPCs) — specialized fibroblasts in hair follicle morphogenesisPyo 2007

Dermal fibroblastsPaccola 2025

Pathway

AHK-Cu → DPC proliferation → VEGF elevation, TGF-β1 suppression → Angiogenesis, follicle elongationPyo 2007

Fibroblast stimulation → Collagen I/III/IV synthesis → Glycosaminoglycan deposition → ECM remodeling

Downstream effect

Stimulates hair follicle elongation ex vivo, reduces dermal papilla cell apoptosis, elevates Bcl-2/Bax ratio, reduces cleaved caspase-3 and PARPPyo 2007

Enhanced extracellular matrix synthesis, improved dermal density, collagen remodelingPaccola 2025

Feedback intact?

—

Origin

Synthetic tripeptide with Cu²⁺ chelation — alanine substitution variant of GHK-Cu

Synthetic pentapeptide KTTKS derived from pro-collagen I fragment, N-palmitoylated for lipophilicityGomes 2022

Antibody development

—

02Dosage Protocols

Parameter

AHK-Cu

Matrixyl

Effective concentration (in vitro)

10⁻¹² – 10⁻⁹ MPyo 2007

Stimulated human hair follicle elongation ex vivo and DPC proliferation in vitro.

—

Topical formulation

0.001–0.01% (estimated cosmetic range)

No standardized human protocol published — extrapolated from in vitro data.

—

Frequency

Once or twice daily (topical application)

—

Route

Topical — scalp or dermal application

—

Evidence basis

Ex vivo hair follicle / in vitro DPC studiesPyo 2007

—

Duration

Not established — cosmetic protocols typically 8–12 weeks

8–12 weeks minimum for visible effect

Collagen synthesis requires sustained application.

Formulation concentration

—

0.5–5% in topical vehicle

Common cosmeceutical range; higher concentrations in clinical formulations.

Application frequency

—

Twice daily (AM/PM)

Standard cosmeceutical protocol.

In vitro evidence

—

Fibroblast viability + ECM gene upregulationPaccola 2025

Vehicle

—

Serum, cream, or emulsion base

Lipophilic carriers enhance penetration.

04Side Effects & Safety

Parameter

AHK-Cu

Matrixyl

Local irritation

Mild erythema, pruritus at application site (copper peptide class effect)

—

Copper sensitivity

Rare hypersensitivity reaction in copper-sensitive individuals

—

Systemic absorption

Minimal via topical route — systemic copper toxicity unlikely at cosmetic doses

Negligible — topical application only

Data limitations

No published human safety trials — cosmetic use presumed safe per class precedent (GHK-Cu)

—

Irritation

—

Mild erythema, pruritus in sensitive skin (rare)

Allergic reaction

—

Contact dermatitis (uncommon)

Absolute Contraindications

AHK-Cu

·Known copper allergy or Wilson's disease

Matrixyl

·Known hypersensitivity to palmitoyl peptides

Relative Contraindications

AHK-Cu

·Broken or inflamed skin (increased absorption risk)
·Concurrent use of other copper-containing formulations

Matrixyl

·Active dermatitis or open wounds at application site

05Administration Protocol

Parameter

AHK-Cu

Matrixyl

1. Topical application

Apply to clean, dry scalp or target dermal area. Typical cosmetic formulations: 0.001–0.01% AHK-Cu in serum or cream base.

Wash face with gentle cleanser. Pat dry.

2. Frequency

Once or twice daily. Evening application preferred for overnight contact time.

Apply 2–3 drops to fingertips. Massage gently into target areas (face, neck, décolletage). Allow 1–2 minutes for absorption.

3. Scalp preparation

For hair growth: apply directly to scalp, massage gently. No need to rinse. Allow absorption for minimum 2–4 hours.

Twice daily — morning and evening. Apply before heavier creams or sunscreen.

4. Storage

Room temperature, protected from light. Copper complexes may degrade in UV exposure.

Store at room temperature, away from direct sunlight. Stable in formulation for 12–24 months.

5. Duration

Minimum 8–12 weeks to assess efficacy in hair growth applications, per typical cosmetic peptide protocols.

—

06Stack Synergy

AHK-Cu

+ GHK-Cu

Moderate

View GHK-Cu →

Both tripeptide-copper complexes share overlapping angiogenic and wound-healing mechanisms (VEGF elevation, TGF-β modulation, fibroblast proliferation). AHK-Cu's alanine substitution may offer distinct receptor affinity or pharmacokinetics. Co-formulation could provide complementary dermal signaling, though no direct synergy studies exist. Often used interchangeably or in alternating protocols.

AHK-Cu: 0.001–0.01% topical · AM
GHK-Cu: 0.001–0.01% topical · PM
Frequency: Daily alternation or combined formulation
Primary benefit: Comprehensive dermal regeneration, angiogenesis, hair follicle support

Matrixyl

+ GHK-Cu

Multi-pathway

View GHK-Cu →

Matrixyl (Pal-KTTKS) stimulates fibroblast collagen synthesis via pro-collagen I mimicry, while GHK-Cu acts as a copper-binding tripeptide that enhances ECM remodeling through metalloproteinase modulation and wound healing pathways. Combined, they address collagen synthesis (Matrixyl) and matrix remodeling/repair (GHK-Cu) through distinct mechanisms, producing complementary effects on dermal architecture.

Matrixyl: 0.5–5% topical serum · AM/PM
GHK-Cu: 1–2% topical serum · same application
Frequency: Twice daily
Primary benefit: Enhanced collagen synthesis + ECM remodeling, improved skin density and elasticity